AWM
MRNA icon

Aberdeen Wealth Management’s Moderna MRNA Stock Holding History

Aberdeen Wealth Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,315
Closed -$275K – 173
2024
Q2 		$275K Hold
2,315
– – 0.19% 126
2024
Q1 		$247K Buy
+2,315
New +$233K 0.14% 137
2023
Q4 		– Sell
-2,315
Closed -$239K – 164
2023
Q3 		$239K Hold
2,315
– – 0.18% 128
2023
Q2 		$281K Hold
2,315
– – 0.2% 121
2023
Q1 		$356K Hold
2,315
– – 0.27% 101
2022
Q4 		$416K Hold
2,315
– – 0.31% 90
2022
Q3 		$274K Hold
2,315
– – 0.24% 108
2022
Q2 		$331K Hold
2,315
– – 0.26% 102
2022
Q1 		$399K Hold
2,315
– – 0.27% 99
2021
Q4 		$588K Hold
2,315
– – 0.38% 72
2021
Q3 		$891K Hold
2,315
– – 0.86% 37
2021
Q2 		$544K Sell
2,315
-1,000
-30% -$179K 0.5% 65
2021
Q1 		$434K Buy
3,315
+175
+6% +$25.4K 0.35% 91
2020
Q4 		$328K Buy
3,140
+234
+8% +$23.7K 0.25% 107
2020
Q3 		$206K Buy
+2,906
New +$203K 0.2% 118

Other funds holding MRNA

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Aberdeen Wealth Management's MRNA Position: Q3 2024 in Review

Aberdeen Wealth Management sold out of Moderna (MRNA) in Q3 2024, closing a stake of 2,315 shares — an estimated $275K sold.

Aberdeen Wealth Management first reported a position in MRNA in Q3 2020 and held it in 15 quarters. The position peaked at $891K in Q3 2021. 788 funds tracked by Wall St. Rank hold MRNA as of Q3 2024.

  • Aberdeen Wealth Management reported no remaining Moderna position as of Q3 2024 after selling out during the quarter.
  • Aberdeen Wealth Management sold 2,315 Moderna shares in Q3 2024, an estimated $275K.
  • Aberdeen Wealth Management first reported a position in Moderna in Q3 2020 and held it in 15 quarters.
  • Aberdeen Wealth Management's Moderna position peaked at $891K in Q3 2021.
  • 788 funds tracked by Wall St. Rank held Moderna as of Q3 2024.

Based on Aberdeen Wealth Management's 13F filing for Q3 2024, filed 8 Nov 2024.